Slow release technology

Standard Mosquito Repellents. Since its initial report as a promising repellent in 1954, DEET has been considered the best all-around repellent having generally acceptable characteristics, despite a continuing search for a superior chemical. Improvements include many commercial products with added cosmetic agents that use slow release technology, such as the U.S. Armed Services slow release 35% DEET formulation (16). There were 35 EPA-registered repellent products in 1994 that contained only DEET under different trade names (2). DEET is present in 192 of the 212 products mentioned previously (2). 

Slow release technology is generally applied to active... 

Slow-Release Fertilizers. Products containing urea—formaldehyde are used to manufacture slow-release fertilisers. These products can be either soHds, Hquid concentrates, orHquid solutions. This market consumes almost 6% of the formaldehyde produced (115) (see Controlled release TECHNOLOGY, AGRICULTURAL). 

The International Landmark Environmental, Inc., Aminoplast Capillary Technology (ACT) is an absorbent product for hydrocarbon and petroleum-based liquids. It can be used for contamination in soil or on surfaces, including liquid surfaces because the material is hydrophobic (will not absorb water) and floats. According to the vendor, ACT also has bioremediative characteristics, acting as a slow release fertilizer, enconraging microbe growth for the break down of toxic waste liquids. 

Finally, for a technology such as microencapsulation that has been recognized for more than 50 years, controlled release is not even close to becoming passe, as over the years a wide variety of alternative slow-release systems have been developed. 

Microporous Various porosity with closed-cell structure (100-1000 A) Mostly bound Combination of molecular diffusion and convection in the water filled pores Slow, sample-size dependent Mainly in biomedical applications and controlled release technology... 

First-in-man clinical trials with the Cypher stent system were performed at the Institute Dante Pazzanese de Cardiologia in the year 2000, comparing a moderate-release cypher stent with a slow-release one in 15 human patients. At the time stent-technology had been an emerging field and this clinical trial helped establish the therapeutic benefits of DBS use by demonstrating slowed neointimal growth in stented patients [1]. 

---